Aditxt (ADTX) Gains from Sales and Divestitures (2021 - 2024)
Aditxt (ADTX) recorded quarterly Gains from Sales and Divestitures of $1.3 million in Q1 2024, up 2897.75% quarter-over-quarter from $44500.0 in Q4 2023, and up 76965.28% on a YoY basis from N/an in Q2 2023.
Aditxt (ADTX) Gains from Sales and Divestitures (2021 - 2024) Analysis & Trends
Aditxt's Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2024.
- In Q1 2024, Gains from Sales and Divestitures rose 76965.28% year-over-year to $1.3 million; the TTM figure through Mar 2024 stood at $1.3 million (up 76965.28% YoY), while the FY2023 annual figure was $44500.0, up 140.46% from the prior year.
- Gains from Sales and Divestitures was $1.3 million for Q1 2024 at Aditxt, up from $44500.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q1 2024 to a low of $4.08 in Q2 2021.
- Historically, Gains from Sales and Divestitures has averaged $180267.3 across 4 years, with a median of $16259.5 in 2021.
- The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures jumped 10425757.84% in 2022, then slumped 99.4% in 2023.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $16519.0 in 2021, then advanced by 12.03% to $18506.0 in 2022, then jumped by 140.46% to $44500.0 in 2023, then soared by 2897.75% to $1.3 million in 2024.
- The last three Gains from Sales and Divestitures figures came in at $1.3 million (Q1 2024), $44500.0 (Q4 2023), and $170.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Aditxt | 2,485.68 | -2.16 Mn | 2,868.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Dec 31, 2023 | 44,500.00 |
| Dec 31, 2023 | 44,500.00 |
| Sep 30, 2023 | 170.00 |
| Sep 30, 2023 | 170.00 |
| Jun 30, 2023 | 3,400.00 |
| Jun 30, 2023 | 3,400.00 |
| Mar 31, 2023 | 1,731.00 |
| Mar 31, 2023 | 1,731.00 |
| Dec 31, 2022 | 18,506.00 |
| Dec 31, 2022 | 18,506.00 |
| Sep 30, 2022 | 15,153.00 |
| Sep 30, 2022 | 15,153.00 |
| Jun 30, 2022 | 425,375.00 |
| Jun 30, 2022 | 425,375.00 |
| Mar 31, 2022 | 287,850.00 |
| Mar 31, 2022 | 287,850.00 |
| Dec 31, 2021 | 16,519.00 |
| Dec 31, 2021 | 16,519.00 |